Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial

Rajendra H. Mehta(Duke University), Sean van Diepen(University of Alberta), James P. Meza(Clinical Research Institute), Paula M. Bokesch(Tenax Therapeutics (United States)), Jeffrey D. Leimberger(Duke University), Sandra Tourt-Uhlig(Duke University), Merri Swartz(Duke University), Jodi Parrotta(Canadian VIGOUR Centre), Rachael Jankowich(Tenax Therapeutics (United States)), Douglas W.P. Hay(Tenax Therapeutics (United States)), Robert W. Harrison(Clinical Research Institute), Stephen E. Fremes(University of Alberta), Shaun G. Goodman(University of Alberta), John M. Luber(Franciscan Health), Wolfgang Toller(University of Graz), Matthias Heringlake(University of Lübeck), Kevin J. Anstrom(Duke University), Jerrold H. Levy(Clinical Research Institute), Robert A. Harrington(Stanford University), John H. Alexander(Duke University)
American Heart Journal
September 13, 2016
Cited by 26

Abstract


Related Papers

No related papers found

Powered by citation graph analysis